The Prevention Agent Pregnancy Exposure Registry, also known as EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) is a prospective observational cohort investigation of exposures to study agents under investigation for HIV prevention. The study population will consist of female participants who are identified as becoming pregnant during their participation in a microbicide or PrEP trial, or who have had planned exposures in pregnancy safety studies as well as their babies resulting from these pregnancies. This study will only enroll babies who have not yet reached their 1 year birth date.
The Prevention Agent Pregnancy Exposure Registry, also known as EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) is a prospective observational cohort study of maternal exposures to investigational HIV prevention agents. Approximately 550 pregnant participants and 400 live infants will be offered enrollment. The study population will consist of current or recent female participants identified as becoming pregnant during microbicide or PrEP trials, or who have had planned exposures in pregnancy safety studies. This study will also include infants resulting from those pregnancies. This protocol will monitor for adverse pregnancy and delivery outcomes, monitor the prevalence of major malformations, evaluate growth parameters of infants during the first year of life, and evaluate the prevalence and persistence of HIV drug resistance mutations in a cohort of infants who were either exposed to active study agents or not exposed to active study agents while in utero.
Study Type
OBSERVATIONAL
Enrollment
873
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Wits Reproductive Health Institute (WRHI)
Johannesburg, Gauteng, South Africa
CAPRISA-The Aurum Institute
Johannesburg, Guateng, South Africa
CAPRISA eThekwini
Durban, KwaZulu-Natal, South Africa
Perinatal HIV Research Unit (PHRU)
Johannesburg, Soweto, South Africa
South African MRC HIV CTU Med Research Council; Botha's Hill Clinical Research Site
Durban, South Africa
South African MRC HIV CTU Med Research Council; Isipingo
Durban, South Africa
South African MRC HIV CTU Med Research Council; Overport
Durban, South Africa
South African MRC HIV CTU Med Research Council; R.K. Khan Hospital
Durban, South Africa
...and 7 more locations
Pregnancy and delivery outcomes comparison
To compare adverse pregnancy and delivery outcomes between participant mothers assigned to an active agent with those of mothers assigned to placebo/control. Pregnancy and delivery outcomes of interest are: * delivery prior to 37 completed weeks of gestation * stillbirth or intrauterine fetal demise (≥ 20 weeks) * spontaneous abortion (\< 20 weeks) * ectopic pregnancy * intrapartum hemorrhage * postpartum hemorrhage * non-reassuring fetal status * chorioamnionitis * hypertensive disorders of pregnancy * gestational diabetes * intrauterine growth restriction
Time frame: Duration of Study
Major malformations comparison
To compare the prevalence of major malformations identified in the first year of life between infants of mothers assigned to an active agent with those of infants of mothers assigned to placebo/control. Major malformations are defined as structural abnormalities with surgical, medical, or cosmetic importance.
Time frame: Duration of Study
Infant growth parameters comparison
To compare growth parameters in the first year of life between infants of mothers assigned to an active agent with those of mothers assigned to placebo/control. Growth parameters of interest are weight, length, and head circumference at birth, one month, six months and 12 months.
Time frame: Duration of Study
HIV drug resistance mutations comparison
2\. To evaluate the prevalence and persistence of HIV drug resistance mutations in plasma among HIV-infected infants.
Time frame: Duration of Study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.